In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1.
about
Antifungal Activity and Action Mechanism of Histatin 5-Halocidin Hybrid Peptides against Candida sspIridoids from Canthium subcordatum iso-butanol fraction with potent biological activitiesMUC7 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal actionHuman salivary mucin MUC7 12-mer-L and 12-mer-D peptides: antifungal activity in saliva, enhancement of activity with protease inhibitor cocktail or EDTA, and cytotoxicity to human cells.Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways.Protection of the oral mucosa by salivary histatin-5 against Candida albicans in an ex vivo murine model of oral infection.New investigational antifungal agents for treating invasive fungal infections.Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts.Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucinsAnti-candidal activity of genetically engineered histatin variants with multiple functional domainsAntimicrobial peptides in the oral environment: expression and function in health and disease.Susceptibility of Candida dubliniensis to salivary histatin 3.The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay.Antimicrobial and antioxidant flavonoids from the leaves of Oncoba spinosa Forssk. (Salicaceae)Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformansAntibacterial and cytotoxic cytochalasins from the endophytic fungus Phomopsis sp. harbored in Garcinia kola (Heckel) nut.Salivary mucins in host defense and disease preventionChemical genomic screening of a Saccharomyces cerevisiae genomewide mutant collection reveals genes required for defense against four antimicrobial peptides derived from proteins found in human saliva.Candida glabrata: an emerging oral opportunistic pathogen.Recent evolution of the salivary mucin MUC7.Anticancer and antibacterial secondary metabolites from the endophytic fungus Penicillium sp. CAM64 against multi-drug resistant Gram-negative bacteria.Role of TGFBIp in Wound Healing and Mucin Expression in Corneal Epithelial Cells.Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries.The properties of the mucus barrier, a unique gel--how can nanoparticles cross it?Elucidating the role of hyposalivation and autoimmunity in oral candidiasis.Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans.Factors affecting antimicrobial activity of MUC7 12-mer, a human salivary mucin-derived peptide.Mucus and Mucins: do they have a role in the inhibition of the human immunodeficiency virus?In vitro inhibitory effect of clove essential oil and its two active principles on tooth decalcification by apple juice.Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1.Fungicidal effect of three new synthetic cationic peptides against Candida albicans.Antifungal activity of histatin-5 against non-albicans Candida species.Proton pumping ATPase mediated fungicidal activity of two essential oil components.Antimicrobial and antioxidant activities of triterpenoid and phenolic derivatives from two Cameroonian Melastomataceae plants: Dissotis senegambiensis and Amphiblemma monticola.Candida parotitis with abscess formationAntimicrobial activities of flavonoid glycosides from Graptophyllum grandulosum and their mechanism of antibacterial actionSynthesis, DNA binding, hemolytic, and anti-cancer assays of curcumin I-based ligands and their ruthenium(III) complexes
P2860
Q27320076-4C12E95A-FF1B-452A-BDDA-2F9174BB4E51Q28365073-21FD641C-EC7D-4F17-92BC-4F77F4B0019DQ29871517-22E566B8-5467-4E29-868E-8E71A659769FQ33836516-68D5FBA7-4CC9-4536-AE81-C865462C5F1AQ33980976-F6FD4C89-B346-4586-83C3-D26C8A0B4E7BQ34067033-052B821D-C525-46F6-A2B2-CED5F6605D47Q34075014-F8C82594-4347-4A77-BF49-0760264E32FDQ34258416-46FD49F3-A23E-4F80-A8FC-FDDAD83A2B62Q34462636-9742A04A-F1E0-4C0A-8E1D-A441EB754F41Q34516733-E53CD3D1-0346-463D-8EF8-314649EC3244Q34684398-636C41A2-8A6F-4AB2-A16B-EE714A9D6A61Q34722920-FAA6CC23-6FD8-4A62-A9F8-DD202191CF6AQ35185496-F71E5C1C-B3E4-4B6D-A6CF-428CD625E937Q35584001-99A2250A-437C-4D37-9A88-ACC9816ACB96Q36001291-20CCAD0E-0DE7-45A7-A3BC-E8B33CC1C115Q36192063-8B3ACFCB-0C2A-494A-8F78-EECCC990BC30Q36400901-33D145AD-E5B0-437E-BFC3-ACA76250F300Q36558457-89E9E1DD-5E4B-4F45-9C71-3E1C8CA363E3Q36741765-CAB0AC70-D7D4-4FC3-A6B1-BDE268052FA6Q37202557-1065B35F-B5D1-452C-8DF5-CF23DAA34EF6Q37418375-9DDE1127-B64E-4419-BB18-7C0A99F5D2FDQ37622176-47422E9A-2BA3-44D5-A47A-691F35349584Q38701785-2B95C384-01A8-4D90-A033-2BBFD365EB5AQ38787318-93DA5EE5-CAAF-470E-88D6-0BAFF71B1F47Q39082425-E11D280D-6388-41F3-A4A3-0569BE02B446Q40160325-864D28AE-B9B8-4E91-98CA-8BD04D1383C8Q41910405-29486092-2794-41A6-B13E-489EDD3DC92FQ41922735-8F27D2FA-5152-4B63-BF94-04B4AD1F7E49Q42322517-A028478F-1D6B-46AF-A13A-D5B9D70D618DQ42589056-4AB1DA8F-09DE-429A-B35D-F40EFB61B55AQ44935554-EF085A31-477E-4EE8-9BA1-447BA0CC9452Q52059435-3C351ED6-A771-4E7C-8049-9A7F79FF4D40Q54545287-8B87264E-8911-4727-A39C-04F28287E193Q55237357-C910D432-5199-4DB8-8835-E38E94B6E332Q58299870-73A09F72-2A8E-4DF0-8490-EB6C1B381F98Q58393448-AC65830B-130E-4C5B-BBE9-4B7781E649A6Q59150140-DBFEE33D-1C5E-458C-A7CD-434464499007
P2860
In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro assessment of antifun ...... alivary mucin (MUC7) domain 1.
@ast
In vitro assessment of antifun ...... alivary mucin (MUC7) domain 1.
@en
type
label
In vitro assessment of antifun ...... alivary mucin (MUC7) domain 1.
@ast
In vitro assessment of antifun ...... alivary mucin (MUC7) domain 1.
@en
prefLabel
In vitro assessment of antifun ...... alivary mucin (MUC7) domain 1.
@ast
In vitro assessment of antifun ...... alivary mucin (MUC7) domain 1.
@en
P2860
P1476
In vitro assessment of antifun ...... alivary mucin (MUC7) domain 1.
@en
P2093
P2860
P304
P356
10.1128/AAC.44.6.1485-1493.2000
P407
P577
2000-06-01T00:00:00Z